| Drug | Mechanism | Onset | Duration | Key Use |
| Nicardipine | Dihydropyridine CCB | 1–2 min | 4–6 h | Neuro emergencies, post-op |
| Clevidipine | Dihydropyridine CCB | <1 min | 5–15 min | Tight perioperative control |
| Labetalol | α/β-blocker | 2–5 min | 3–6 h | General, pregnancy-safe |
| Esmolol | β₁-selective blocker | 1 min | 10–20 min | Tachyarrhythmias, aortic dissection |
| Nitroprusside | Direct NO donor | Seconds | 1–2 min | Refractory, pulmonary edema (cyanide risk) |
| Nitroglycerin | Venous > arterial dilation | 1–2 min | 3–5 min | Acute coronary syndrome, pulmonary edema |
| Hydralazine | Direct arterial dilator | 10–20 min (IV) | 4–6 h | Pregnancy (avoid in coronary disease) |
| Fenoldopam | D₁ agonist (renal vasodilation) | 5 min | 30–60 min | Renal-protective |
Rapid Oral Agents (Urgent, Not Emergent)
- Nifedipine IR (avoid — reflex tachycardia/stroke risk) — not recommended.
- Clonidine 0.1–0.2 mg PO: Central α₂ agonist; 30–60 min.
- Captopril 12.5–25 mg PO: ACEi; 15–30 min.
- Labetalol 200 mg PO: 1–2 hrs.
Critical Principles
- Never use sublingual nifedipine — associated with stroke/MI.
- Lower MAP by ≤25% in first hour (except aortic dissection: target SBP <120 in 20 min).
- Continuous arterial monitoring required for IV agents.
- Oral agents for urgency (asymptomatic severe HTN); IV for emergency (target organ damage).
Always under physician supervision. Inappropriate rapid lowering causes cerebral/renal/coronary hypoperfusion.
Blood Disorders - Related Articles